Claude Nicaise Biography and Net Worth

Director of Sarepta Therapeutics

Claude Nicaise, M.D. has served as a member of our Board since June 2015. He also serves as a member of our compensation committee and as a member of our research and development committee.

Dr. Nicaise is the owner of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies. Since January 2017, Dr. Nicaise has served as a member of the board of directors for Minoryx. Since February 2021, Dr. Nicaise has served as a member of the board of directors and on the compensation committee of Gain Therapeutics. Since March 2021, Dr. Nicaise has served as a member of the board of directors and on the audit committee of Chemomab. In September 2024, Dr. Nicaise was appointed as Cassava’s Chairman. He has served as a director of Cassava since December 2023. He served as an Executive Vice President Regulatory at Ovid Therapeutics Inc., a company that develops medicines for orphan diseases of the brain, from 2015 to March 2023. From 2008 to 2014, Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals Inc., a pharmaceutical company. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including the following senior management positions: Vice-President of Global Development, Vice-President Worldwide Regulatory Science and Strategy and leadership positions in Oncology, Infectious Disease and NeuroScience Development.

Dr. Nicaise holds an M.D. from the Universite libre de Bruxelles in Belgium.

What is Claude Nicaise's net worth?: The estimated net worth of Claude Nicaise is at least $2.70 million as of March 12th, 2025. Nicaise owns 27,812 shares of Sarepta Therapeutics stock worth more than $2,703,048 as of March 15th. This net worth estimate does not reflect any other assets that Nicaise may own. Learn More about Claude Nicaise's net worth.
How do I contact Claude Nicaise?: The corporate mailing address for Nicaise and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (617) 274-4000 and via email at investors@sarepta.com. Learn More on Claude Nicaise's contact information.
Has Claude Nicaise been buying or selling shares of Sarepta Therapeutics?: During the last quarter, Claude Nicaise has sold $248,203.24 of Sarepta Therapeutics stock. Most recently, Claude Nicaise sold 2,491 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a transaction totalling $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. Learn More on Claude Nicaise's trading history.
Who are Sarepta Therapeutics' active insiders?: Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Claude Nicaise (Director), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?: In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 71,063 shares worth more than $10,672,909.13. The most recent insider tranaction occured on March, 12th when Director Claude Nicaise sold 2,491 shares worth more than $248,203.24. Insiders at Sarepta Therapeutics own 7.7% of the company. Learn More about insider trades at Sarepta Therapeutics.
Information on this page was last updated on 3/12/2025.

Claude Nicaise Insider Trading History at Sarepta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/12/2025	Sell	2,491	$99.64	$248,203.24	27,812

Claude Nicaise Buying and Selling Activity at Sarepta Therapeutics

Sarepta Therapeutics Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $97.19

$97.06

$100.00

50 Day Range

MA: $111.73

$97.19

$127.89

2 Week Range

Now: $97.19

$97.06

$173.25

Volume

874,067 shs

Average Volume

916,983 shs

Market Capitalization

$9.43 billion

P/E Ratio

77.75

Dividend Yield

N/A

Beta

0.79